The effects of imaging markers on clinical trajectory in cerebral amyloid angiopathy: a longitudinal study in a memory clinic

Table 3 Effects of imaging markers on longitudinal cognitive trajectory obtained from the mixed effects model

Outcome	Fixed effect	Estimate of fixed effect × time on outcome
Outcome	Fixed effect	B (SE)	p^†
MMSE		− 0.44 (0.3)
	Presence of cSS	− 0.14 (0.11)	0.133
	ln(1 + lobar CMBs)	0.04 (0.37)	0.186
	Previous lobar ICH	− 0.57 (0.28)	0.917
	Severe CSO-EPVS	0.01 (0.29)	0.984
	Multi-spot WMH	− 0.48 (0.28)	0.089
	Presence of CMI	− 1.1 (0.36)	0.045
	Aβ positivity	− 0.44 (0.3)	0.002
CDR-SB	Presence of cSS	− 0.44 (0.3)	0.133
	ln(1 + lobar CMBs)	0.04 (0.37)	0.917
	Previous lobar ICH	− 0.34 (0.29)	0.230
	Severe CSO-EPVS	− 0.44 (0.3)	0.440
	Multi-spot WMH	0.04 (0.37)	0.488
	Presence of CMI	− 0.06 (0.23)	0.781
	Aβ positivity	0.55 (0.28)	0.050

Abbreviations: OR, odds ratio; CI, confidence interval; cSS, cortical superficial siderosis; CMBs, cerebral microbleeds; ICH, intracerebral hemorrhage; CSO-EPVS, enlarged perivascular space in centrum semiovale; CMI, cortical microinfarcts; WMH, white matter hyperintensity; CMI, cortical microinfarct; MMSE, Mini-Mental Status Examination; CDR-SB, Clinical Dementia Rating Sum of Boxes; Aβ, amyloid β
^†P value (significance) for effects of each imaging marker on longitudinal cognitive changes (= significance for the interaction term of each imaging marker and time interval) obtained from linear mixed effect model

ISSN: 1758-9193